Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Non-small Cell Lung Cancer
- Registration Number
- NCT00200382
- Lead Sponsor
- Rasim Gucalp
- Brief Summary
The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
- Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma)stage III B or Stage IV.
No prior chemotherapy regimen Patients must have adequate organ and marrow function
Exclusion Criteria
- Untreated symptomatic brain metastasis Patients with known HIV positivity
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
HealthAlliance Hospitals
🇺🇸Fitchburg, Massachusetts, United States
Jacobi Medical Center
🇺🇸Bronx, New York, United States
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Albert Einstein Cancer Center
🇺🇸Bronx, New York, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States